Azathioprine is an immunosuppressive drug that works by interfering with the production of DNA and RNA in rapidly dividing cells, particularly the white blood cells that drive immune responses. It is a prodrug, meaning your body must convert it into active compounds before it does anything useful. Once those active compounds reach immune cells, they disrupt cell replication and trigger cell death through several overlapping pathways. The drug has been a workhorse in transplant medicine and autoimmune disease management for decades, but its effectiveness comes with a real set of risks that require careful monitoring.
How Azathioprine Suppresses the Immune System
After you swallow an azathioprine tablet, your body converts it into 6-mercaptopurine (6-MP), which is then further broken down into several active metabolites. The most important of these are called 6-thioguanine nucleotides (6-TGNs). These molecules are structurally similar enough to the building blocks of DNA and RNA that your cells mistakenly incorporate them during replication. When 6-TGN gets slotted into a growing DNA strand, it stalls the process, leading to defective DNA, halted cell division, and eventually cell death.1PubMed Central. Azathioprine: old drug, new actions
That alone would be enough to slow down the immune system, but azathioprine has a second trick. Another metabolite, thio-inosine monophosphate (TIMP), blocks an enzyme pathway the body uses to build new purines from scratch. Purines are essential components of DNA, so shutting down their production starves rapidly dividing cells of the raw materials they need. Immune cells, which multiply aggressively during an inflammatory response, are hit especially hard.
Research has revealed a third, more targeted mechanism. One of azathioprine’s metabolites, 6-thioguanine triphosphate, binds to a signaling protein called Rac1 inside T cells. Normally, Rac1 helps T cells receive the “go” signal from other immune cells. When 6-thioguanine triphosphate locks onto Rac1, it prevents that activation, and the T cell self-destructs through a process called apoptosis.1PubMed Central. Azathioprine: old drug, new actions This targeted killing of activated T cells helps explain why azathioprine can dampen an overactive immune response without completely wiping out your immune defenses.
Conditions Treated with Azathioprine
Azathioprine’s broadest use is in inflammatory bowel disease (IBD), covering both Crohn’s disease and ulcerative colitis. It is typically reserved for patients who cannot taper off steroids without their disease flaring back up. A long-term study of 394 patients found that azathioprine achieved partial response or remission in the majority of both Crohn’s and ulcerative colitis patients, and dramatically cut steroid dependence: in Crohn’s patients, steroid use dropped from about half of patients before treatment to roughly 8% afterward, with similar reductions in ulcerative colitis.2PubMed. Comparative effectiveness of azathioprine in Crohn’s disease and ulcerative colitis: prospective, long-term, follow-up study of 394 patients That steroid-sparing effect is a major reason clinicians reach for the drug, because long-term steroid use carries its own brutal list of side effects.
In organ transplantation, azathioprine has been used for decades to help prevent the body from rejecting a donated kidney, liver, or heart. One randomized trial comparing it head-to-head with mycophenolate mofetil (a newer immunosuppressant) in kidney transplant recipients found that azathioprine performed just as well at preventing acute rejection, despite being roughly fifteen times cheaper.3The Lancet. Mycophenolate mofetil versus azathioprine as part of maintenance immunosuppression to prevent acute rejection in renal transplantation (MYSS): a randomised trial
Azathioprine also plays a role in managing systemic lupus erythematosus (SLE). It is given to lupus patients who need ongoing steroid doses to control flares, particularly those with kidney involvement, resistant skin lesions, or blood abnormalities like low platelet counts.4PubMed. Azathioprine therapy for patients with systemic lupus erythematosus Beyond IBD, transplant, and lupus, you will find it prescribed for a range of other autoimmune conditions including myasthenia gravis, autoimmune hepatitis, and certain vasculitides. It tends to be the workhorse drug that clinicians turn to when the disease requires long-term immune suppression and biologics are either unavailable, too expensive, or inappropriate.
The Allopurinol Interaction
If there is one drug interaction every person on azathioprine needs to know about, it is allopurinol. Allopurinol is commonly prescribed for gout, and the combination can be dangerous.
Under normal circumstances, a significant portion of 6-mercaptopurine (the active breakdown product of azathioprine) gets deactivated by an enzyme called xanthine oxidase. Allopurinol blocks xanthine oxidase. When both drugs are taken together, the metabolic pathway that normally clears 6-mercaptopurine is shut down, and the drug’s active metabolites build up to toxic levels. The result can be severe bone marrow suppression, with life-threatening drops in white blood cells, red blood cells, and platelets.5PubMed Central. Pancytopenia caused by allopurinol and azathioprine interaction in a heart transplant patient: a case report
This interaction is well documented and entirely predictable, yet it continues to catch patients and occasionally prescribers off guard. A review from New Zealand’s medicines safety authority flagged the combination as capable of causing “life-threatening” blood disorders including pancytopenia.6Prescriber Update. Azathioprine-Allopurinol Interaction: Danger! If your doctor decides that both drugs are genuinely necessary, the azathioprine dose typically needs to be cut to about a quarter of the usual amount, with very close blood monitoring. But in most cases, clinicians simply avoid the combination altogether.
Bone Marrow Suppression and Blood Monitoring
The most feared acute side effect of azathioprine is myelosuppression, a broad term for the drug damaging your bone marrow’s ability to produce blood cells. This can show up as a drop in white blood cells (making you vulnerable to infections), a drop in platelets (increasing bleeding risk), or in the worst cases, pancytopenia, where all blood cell lines crash simultaneously.
A 27-year study of 739 IBD patients on azathioprine found that about 5% developed some degree of bone marrow toxicity. Most were caught early through routine blood tests and had no symptoms. But severe drops in white blood cell counts did occur, and among those patients, two died of sepsis.7PubMed Central. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience The timing was unpredictable: bone marrow toxicity appeared anywhere from two weeks to eleven years after starting the drug, sometimes developing suddenly and sometimes creeping up over months.
This unpredictability is exactly why regular blood count monitoring is non-negotiable for anyone taking azathioprine. Most guidelines call for blood tests every one to two weeks when starting the drug, spacing out to every few months once the dose is stable. Data on metabolite levels show that patients whose 6-TGN concentrations climb above the therapeutic range face a much higher rate of myelosuppression compared to those within range.8PubMed Central. Pharmacology of Thiopurine Therapy in Inflammatory Bowel Disease and Complete Blood Cell Count Outcomes: A 5-Year Database Study That makes metabolite testing a useful safety tool alongside standard blood counts.
Genetic Testing Before Starting Treatment
Not everyone metabolizes azathioprine the same way, and for a small percentage of people, the drug is essentially a poison at standard doses. The key enzyme responsible for breaking down 6-mercaptopurine into inactive products is called TPMT. Roughly one in 200 to one in 300 people of European descent carry genetic variants that leave them with very low TPMT activity. A case report of fatal azathioprine toxicity documented a patient who was found, during her final hospital admission, to carry such a variant, making her extremely sensitive to myelosuppression at a normal dose.9Australian Prescriber. Fatal azathioprine toxicity
TPMT testing has become standard practice in many countries before starting azathioprine. But TPMT is not the whole story. A second enzyme, NUDT15, plays an important role in azathioprine metabolism, and its genetic variants are far more common in East Asian populations. A study of Chinese patients found that the NUDT15 R139C variant was strongly associated with azathioprine-induced drops in white blood cells, with carriers facing over twenty times the odds of developing that complication.10PubMed Central. Implementation of NUDT15 Genotyping to Prevent Azathioprine-Induced Leukopenia for Patients With Autoimmune Disorders in Chinese Population A separate study of patients in southwest China with autoimmune hepatitis confirmed the strong association between NUDT15 variants and both low white blood cell counts and low neutrophil counts, while finding no significant link for TPMT variants in that population.11Scientific Reports. Association of genetic variants in TPMT, ITPA, and NUDT15 with azathioprine-induced myelosuppression in southwest china patients with autoimmune hepatitis
The practical takeaway is that TPMT testing alone is not sufficient for patients of East Asian descent. Many institutions are now incorporating NUDT15 genotyping into their pre-treatment workup. If testing reveals intermediate or absent enzyme activity for either gene, your doctor will either reduce the dose sharply or choose a different drug entirely. This kind of pharmacogenomic screening is one of the clearest examples in medicine of a genetic test directly changing prescribing decisions.
Metabolite Testing and Dose Optimization
Even with normal genetics, azathioprine dosing is not simple. The drug gets metabolized along competing pathways: one produces the therapeutically active 6-TGN, while another produces 6-methylmercaptopurine (6-MMP), a metabolite linked to liver damage. Some patients end up shunting most of the drug toward 6-MMP instead of 6-TGN, which means they get the toxicity without the benefit.12PubMed Central. Optimizing 6-mercaptopurine and azathioprine therapy in the management of inflammatory bowel disease
Metabolite testing measures the levels of both 6-TGN and 6-MMP in red blood cells. The target therapeutic range for 6-TGN is generally considered to be around 235 to 260 pmol per 8 × 10⁸ red blood cells.13PubMed Central. A Physician’s Guide to Azathioprine Metabolite Testing If a patient’s 6-TGN is below the therapeutic range, the dose may be increased. If 6-MMP is sky-high while 6-TGN is low, simply raising the dose will not fix the problem and will likely cause liver toxicity. In those cases, doctors can add low-dose allopurinol (paradoxically, given the interaction described earlier, but at carefully controlled doses) to redirect metabolism toward 6-TGN, or they may switch to a different drug altogether. This kind of therapeutic drug monitoring is becoming increasingly routine in IBD clinics.14PubMed. Clinical utility of thiopurine metabolite levels in monitoring patients with inflammatory bowel disease: A single-centre retrospective study
Skin Cancer Risk and the UVA Connection
Long-term azathioprine use raises the risk of certain skin cancers, and the mechanism is more specific than just “immunosuppression lowers cancer surveillance.” When 6-thioguanine gets incorporated into the DNA of skin cells, it creates a chemical vulnerability to ultraviolet A (UVA) light. UVA makes up more than 90% of the ultraviolet radiation that reaches us at ground level, and normal DNA handles it reasonably well. But DNA containing 6-thioguanine reacts with UVA to generate reactive oxygen species, which cause mutations.15PubMed Central. Azathioprine and UVA light generate mutagenic oxidative DNA damage This has been confirmed in skin biopsies from patients taking therapeutic doses, where researchers detected 6-thioguanine in skin DNA and measured abnormal photosensitivity to UVA.16PubMed. Azathioprine treatment photosensitizes human skin to ultraviolet A radiation
A meta-analysis of organ transplant recipients found that azathioprine exposure was associated with about a 56% increase in the risk of squamous cell carcinoma (SCC), a type of skin cancer strongly linked to cumulative UV damage.17PubMed. Azathioprine and Risk of Skin Cancer in Organ Transplant Recipients: Systematic Review and Meta-Analysis The same analysis did not find a significant increase in basal cell carcinoma. In a separate study of myasthenia gravis patients, the incidence rate of nonmelanoma skin cancer among those who had taken azathioprine was roughly 16 times higher than expected, with all confirmed cases occurring in patients who had been on the drug for at least six months. No skin cancers appeared in untreated patients.18PubMed Central. Nonmelanoma skin cancer risk awareness in azathioprine‐treated myasthenia gravis patients
The encouraging finding is that this photosensitivity appears to be at least partly reversible. A study of kidney transplant recipients who switched from azathioprine to mycophenolate mofetil showed that UVA skin sensitivity and DNA damage markers improved after the switch.19PubMed. Reversal of UVA skin photosensitivity and DNA damage in kidney transplant recipients by replacing azathioprine For patients who stay on the drug, aggressive sun protection is not optional. Sunscreen, protective clothing, and regular skin checks with a dermatologist become genuinely important medical advice rather than generic lifestyle suggestions.
Liver Toxicity and Nodular Regenerative Hyperplasia
Besides bone marrow suppression and skin cancer, azathioprine can damage the liver. The most common form is a dose-related hepatotoxicity linked to high 6-MMP metabolite levels, which usually shows up as elevated liver enzymes on blood tests and typically resolves when the dose is reduced or the drug is stopped.
A rarer but more serious liver complication is nodular regenerative hyperplasia (NRH), where the liver develops small clusters of regenerating cells that distort its architecture. A study identifying 37 cases of NRH in IBD patients treated with azathioprine found that the condition developed after a median of four years on the drug, with a wide range from 6 months to over 15 years. After follow-up, more than a third of those patients went on to develop complications of portal hypertension, a sign of significant liver damage.20PubMed Central. Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine NRH can be tricky to detect because standard liver function tests may be normal or only mildly abnormal; the first clue is sometimes an unexplained drop in platelet count or signs of portal hypertension such as an enlarged spleen.
Azathioprine Versus Mycophenolate Mofetil
Mycophenolate mofetil (MMF) is often positioned as the modern alternative to azathioprine. Whether it is actually better depends heavily on what you are treating. In kidney transplant recipients receiving modern immunosuppression regimens, azathioprine performed comparably to MMF at preventing rejection while costing a fraction of the price.3The Lancet. Mycophenolate mofetil versus azathioprine as part of maintenance immunosuppression to prevent acute rejection in renal transplantation (MYSS): a randomised trial
In autoimmune hepatitis, the picture is different. A meta-analysis found that MMF achieved biochemical remission in roughly 89% of patients compared to about 54% for azathioprine, and MMF was effective in a majority of patients who had either not responded to or could not tolerate azathioprine.21PubMed Central. Efficacy and Safety of Mycophenolate Mofetil Compared to Azathioprine in Autoimmune Hepatitis: A Meta-Analysis Side effect rates and overall survival did not differ between the two drugs in that analysis.
For myasthenia gravis, a prospective study comparing the two found a trend toward better quality-of-life scores with MMF, but the differences did not reach statistical significance. The side effect profiles diverged in expected ways: liver problems were more common with azathioprine (about 15% of patients), while gastrointestinal upset was the main issue with MMF (also about 15%).22PubMed. Comparative effectiveness of azathioprine and mycophenolate mofetil for myasthenia gravis (PROMISE-MG): a prospective cohort study The bottom line is that azathioprine holds up reasonably well in many head-to-head comparisons, but MMF tends to be the go-to switch when azathioprine either fails or causes intolerable side effects.
Infections and Vaccine Considerations
Because azathioprine dampens immune function, it increases your susceptibility to infections. This is not just a theoretical concern. People on immunosuppressive therapy for IBD and other conditions get vaccine-preventable illnesses at higher rates than the general population, and the risk is compounded by the fact that many of these patients do not receive routine preventive care at the same rates as others.23PubMed Central. Vaccination and Health Maintenance Issues to Consider in Patients With Inflammatory Bowel Disease
Live vaccines (such as the older oral polio vaccine, live-attenuated shingles vaccine, or yellow fever vaccine) are generally contraindicated while you are on azathioprine, because the weakened viruses can cause actual disease in an immunosuppressed person. Inactivated vaccines are safe to give, though the immune response may be blunted, meaning the vaccine might not work as well. For this reason, guidelines typically recommend getting your vaccinations up to date before starting azathioprine whenever the disease timeline allows it. Annual flu shots and pneumococcal vaccines are specifically encouraged.
Pregnancy and Breastfeeding
Azathioprine has a complicated reputation when it comes to pregnancy. It was historically avoided during pregnancy due to animal studies suggesting birth defects, and it carries a pregnancy category warning in several countries. However, the human data tell a more reassuring story. A growing body of evidence from prospective cohort studies suggests that azathioprine is safe for the fetus during pregnancy.24PubMed Central. Safety of azathioprine use during pregnancy The fetal liver lacks the enzyme needed to convert azathioprine into its active metabolites, which provides a degree of natural protection.
For breastfeeding, a case series found no clinically significant effects on the blood counts or immune function of babies whose mothers were taking azathioprine.25PubMed Central. Is breastfeeding safe with azathioprine? The short-term data are encouraging, though large-scale long-term studies are still lacking. Current gastroenterology and rheumatology guidelines generally consider azathioprine compatible with both pregnancy and breastfeeding, largely because the risks of uncontrolled autoimmune disease during pregnancy typically outweigh the risks of continued treatment.
Azathioprine in Cats
Azathioprine is occasionally prescribed by veterinarians for immune-mediated conditions in dogs, where it is generally tolerated at appropriate doses. Cats, however, are a different matter entirely. A controlled study of cats given azathioprine at the standard dog dosing protocol found that every single treated cat developed profound neutropenia. One developed pancytopenia. When one cat was rechallenged at half the dose, neutropenia recurred within two weeks. Bone marrow biopsies revealed severely depleted marrow, and two cats developed respiratory infections during the study, one of which had to be euthanized.26PubMed. Systemic toxicosis associated with azathioprine administration in domestic cats Cats appear to be exquisitely sensitive to azathioprine’s myelosuppressive effects, and the drug is now widely considered contraindicated in felines. If your cat has been diagnosed with an immune-mediated condition, the treatment protocol will look very different from what a dog or a human would receive.